Personalized care platform Mymee operates as a personalized trial and care platform for autoimmune diseases and long COVID, presenting a sales angle to healthcare providers and patient groups seeking targeted, patient-driven management solutions.

Strategic partnerships Recent collaboration with Covid Care Group indicates appetite for partnerships that expand reach into long COVID recovery services, suggesting opportunities to co-sell or integrate with nutrition, rehabilitation, or telehealth networks.

Award-winning credibility Recognition such as the World Changing Ideas award enhances credibility when approaching health systems and payers, aiding storytelling around impact, innovation, and measurable outcomes.

Early-stage traction Revenue under one million with secured funding of 8.7 million signals a growth-ready startup environment, ideal for pilots, value-based pricing pilots, and expansion into adjacent autoimmune care markets.

Tech-enabled operations Tech stack leveraging AWS, Salesforce, and data tools indicates readiness for scalable deployments, data integration with EHR workflows, and analytics-driven patient engagement opportunities.